ROS1 and non-small cell lung carcinoma: Based on a retrospective analysis of the efficacy of ceritinib in the treatment of ROS1-positive NSCLC patients after the development of crizotinib resistance, ceritinib can be used as a treatment option after the development of crizotinib resistance.